CJM112
Sponsors
Novartis Pharmaceuticals, Novartis
Conditions
Acne VulgarisAsthmaChronic Plaque-type PsoriasisColorectal Cancer, Triple Negative Breast Cancer, NSCLC - AdenocarcinomaHidradenitis Suppurativa (Acne Inversa)Multiple Myelomaacne
Phase 1
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
CompletedNCT01828086
Start: 2013-06-30End: 2015-10-31Updated: 2020-12-11
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
CompletedNCT02900664
Start: 2016-08-23End: 2021-03-17Updated: 2022-03-29
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
CompletedNCT03111992
Start: 2017-12-18End: 2020-03-02Updated: 2022-02-09
Phase 2
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
CompletedNCT02421172
Start: 2015-04-13End: 2016-11-23Updated: 2022-07-13
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
CompletedNCT02998671
Start: 2016-12-22End: 2018-08-01Updated: 2022-07-12
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
CompletedNCT03299686
Start: 2017-11-06End: 2019-07-08Updated: 2021-10-08
A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne
Active, not recruitingNL-OMON47130
Start: 2016-12-22Target: 30Updated: 2024-02-28